OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan
Frank Lloyd Dini, Erberto Carluccio, Roberto Bitto, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 2, pp. 1107-1117
Open Access | Times Cited: 18
Frank Lloyd Dini, Erberto Carluccio, Roberto Bitto, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 2, pp. 1107-1117
Open Access | Times Cited: 18
Showing 18 citing articles:
Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial
Farnosh Masmoo, Farnaz Fariba, Nakisa Khansari, et al.
Journal of Pharmacy And Bioallied Sciences (2025)
Open Access
Farnosh Masmoo, Farnaz Fariba, Nakisa Khansari, et al.
Journal of Pharmacy And Bioallied Sciences (2025)
Open Access
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples
Erberto Carluccio, Frank Lloyd Dini, Michele Correale, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 6, pp. 856-865
Open Access | Times Cited: 9
Erberto Carluccio, Frank Lloyd Dini, Michele Correale, et al.
Clinical Research in Cardiology (2023) Vol. 113, Iss. 6, pp. 856-865
Open Access | Times Cited: 9
The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population
Giuseppe Dattilo, Giulia Laterra, Roberto Licordari, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6247-6247
Open Access | Times Cited: 7
Giuseppe Dattilo, Giulia Laterra, Roberto Licordari, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6247-6247
Open Access | Times Cited: 7
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better
Francesco Loria, Pasquale Mone, Antonella Rispoli, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Francesco Loria, Pasquale Mone, Antonella Rispoli, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score
Yoav Granot, Y. J. Meir, Michal Laufer Perl, et al.
Clinical Research in Cardiology (2024)
Open Access | Times Cited: 1
Yoav Granot, Y. J. Meir, Michal Laufer Perl, et al.
Clinical Research in Cardiology (2024)
Open Access | Times Cited: 1
Current Review of Heart Failure-Related Risk and Prognostic Factors
Michał Maksymilian Wilk, Jakub Wilk, Szymon Urban, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 1
Michał Maksymilian Wilk, Jakub Wilk, Szymon Urban, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 1
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
Iacopo Fabiani, Nicola Riccardo Pugliese, Gianni Pedrizzetti, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2927-2938
Open Access | Times Cited: 3
Iacopo Fabiani, Nicola Riccardo Pugliese, Gianni Pedrizzetti, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2927-2938
Open Access | Times Cited: 3
Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
Qingsong Chen, Yunlin Chen, Fang Qin, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Qingsong Chen, Yunlin Chen, Fang Qin, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 5
Irreversible myocardial injury attenuates the benefits of sacubitril/valsartan in heart failure patients
Hong‐Mi Choi, In‐Chang Hwang, Hye Jung Choi, et al.
International Journal of Cardiology (2023) Vol. 397, pp. 131611-131611
Closed Access | Times Cited: 2
Hong‐Mi Choi, In‐Chang Hwang, Hye Jung Choi, et al.
International Journal of Cardiology (2023) Vol. 397, pp. 131611-131611
Closed Access | Times Cited: 2
Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
Sheldon E. Litwin, Cara East
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 4
Sheldon E. Litwin, Cara East
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 4
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry
Lars H. Lund, Uwe Zeymer, Andrew L. Clark, et al.
International Journal of Cardiology (2022) Vol. 370, pp. 279-286
Closed Access | Times Cited: 3
Lars H. Lund, Uwe Zeymer, Andrew L. Clark, et al.
International Journal of Cardiology (2022) Vol. 370, pp. 279-286
Closed Access | Times Cited: 3
Correction to “Impact analysis of heart failure across European countries: an ESC‐HFA position paper” and “Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan”
Massimo Piepoli
ESC Heart Failure (2024) Vol. 11, Iss. 2, pp. 1280-1280
Open Access
Massimo Piepoli
ESC Heart Failure (2024) Vol. 11, Iss. 2, pp. 1280-1280
Open Access
Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
Michele Correale, Giuseppe Pelaggi, Maria Concetta Catanoso, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 5, pp. 1135-1143
Closed Access
Michele Correale, Giuseppe Pelaggi, Maria Concetta Catanoso, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 5, pp. 1135-1143
Closed Access
Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study
Alberto Palazzuoli, Filippo Pirrotta, Alessandra Cartocci, et al.
Therapeutic Advances in Cardiovascular Disease (2024) Vol. 18
Open Access
Alberto Palazzuoli, Filippo Pirrotta, Alessandra Cartocci, et al.
Therapeutic Advances in Cardiovascular Disease (2024) Vol. 18
Open Access
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy
Frank Lloyd Dini, Erberto Carluccio, Stefano Ghio, et al.
Heart Failure Reviews (2023) Vol. 29, Iss. 2, pp. 367-378
Closed Access | Times Cited: 1
Frank Lloyd Dini, Erberto Carluccio, Stefano Ghio, et al.
Heart Failure Reviews (2023) Vol. 29, Iss. 2, pp. 367-378
Closed Access | Times Cited: 1
Risk Stratification of Patients With Decompensated Heart Failure by Echocardiographic Assessment of Hemodynamics
Mark H. Drazner
The American Journal of Cardiology (2023) Vol. 207, pp. 280-282
Closed Access | Times Cited: 1
Mark H. Drazner
The American Journal of Cardiology (2023) Vol. 207, pp. 280-282
Closed Access | Times Cited: 1
Prognostic significance of resting cardiac power to left ventricular mass and E/e’ ratio in heart failure with preserved ejection fraction
Cong Chen, Jie Zhao, Ruicong Xue, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 2
Cong Chen, Jie Zhao, Ruicong Xue, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 2
